Riccardo Pravisani, Ailton Sepulveda, Lorenzo Cocchi, Estrella Mello, Francois Cauchy, Safi Dokmak, Olivier Farges, Francois Durand, Emmanuel Weiss, Federica Dondero, Mickaël Lesurtel – 23 June 2022 – In liver transplantation (LT), graft aberrant hepatic arteries (aHAs) frequently require complex arterial reconstructions, potentially increasing the risk of post‐operative complications. However, intrahepatic hilar arterial shunts are physiologically present and may allow selective aHA ligation.

Bing Chen, Yichen Wang, Marcia Lange, Tatyana Kushner – 23 June 2022 – Prior international studies have shown mixed results regarding the association of hepatitis B and hepatitis C with adverse pregnancy outcomes. We performed an updated evaluation of the prevalence of associated adverse pregnancy outcomes and evaluated trends over time of diagnosis of chronic hepatitis B (HBV) and chronic hepatitis C (HCV) in pregnant women in a national database. All pregnant women with HBV and HCV were identified from the National Inpatient Sample database 2012 to 2018.

Mary Thomson, John R. Lake – 23 June 2022

Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates – 22 June 2022 – Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH).

Eleanor Barnes, Graham S. Cooke, Georg M. Lauer, Raymond T. Chung – 22 June 2022 – Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral (DAA) drugs have transformed the treatment of HCV. However, it has become clear that, without an effective HCV vaccine, it will not be possible to meet the World Health Organization targets of HCV viral elimination. Promising new vaccine technologies that generate high magnitude antiviral T and B cell immune responses and significant new funding have recently become available, stimulating the HCV vaccine pipeline.

Christian E. Oberkofler, Dimitri A. Raptis, Philip C. Müller, Richard X. Sousa da Silva, Kuno Lehmann, Takahiro Ito, Timothy Owen, Joerg‐Matthias Pollok, Alessandro Parente, Andrea Schlegel, Peregrina Peralta, Erin Winter, Markus Selzner, Margot Fodor, Manuel Maglione, Manuel Jaklitsch, Hugo P. Marques, Mariana Chavez‐Villa, Alan Contreras, Philipp Kron, Peter Lodge, Scott Alford, Abbas Rana, Paolo Magistri, Fabrizio Di Benedetto, Bethany Johnson, Varvara Kirchner, Francis Bauldrick, Karim J. Halazun, Omid Ghamarnedjad, Arianeb Mehrabi, Samanta Teixeira Basto, Eduardo S. M.

Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas – 22 June 2022

Katherine E. Lindblad, Amaia Lujambio – 20 June 2022

Alexandra T. Strauss, Carolyn N. Sidoti, Tanjala S. Purnell, Hannah C. Sung, John W. Jackson, Scott Levin, Vedant S. Jain, Daniel Malinsky, Dorry L. Segev, James P. Hamilton, Jacqueline Garonzik‐Wang, Stephen H. Gray, Macey L. Levan, Joseph R. Scalea, Andrew M. Cameron, Ahmet Gurakar, Ayse P. Gurses – 20 June 2022 – Racial and ethnic disparities persist in access to the liver transplantation (LT) waiting list; however, there is limited knowledge about underlying system‐level factors that may be responsible for these disparities.

Ka‐Hei Lam, Stephanie Ma – 20 June 2022 – Cancer stem cells (CSCs) are now recognized as one of the major root causes of therapy failure and tumor recurrence in hepatocellular carcinoma (HCC). Early studies in the field focused primarily on the intrinsic regulators of CSC maintenance, but in recent years, mounting evidence has demonstrated the presence and role of extrinsic regulators in the tumor microenvironment (TME) in the control of liver CSCs.